COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ — Curasight A/S (“Curasight” or “the Company” – (CPH: CURAS) a clinical-stage theranostic company focused on diagnosingCOPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ — Curasight A/S (“Curasight” or “the Company” – (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing

Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

2026/01/05 18:15
2 min read

COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ — Curasight A/S (“Curasight” or “the Company” – (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain types of cancers, announced that CEO Ulrich Krasilnikoff and CMO prof. Andreas Kjær will be in San Francisco during the 44th J.P. Morgan Healthcare Conference being held January 12-15, 2026.

During the week, Curasight management will hold meetings with investors and other industry stakeholders. The meetings will include updates on the Company’s clinical progress, including the recent initiation of a Phase 1 trial with uTREAT® in aggressive brain cancer, and the ongoing Phase 2 trial of uTRACE® in prostate cancer conducted in partnership with Curium Inc.

About the uPAR theranostic platform

Curasight’s uPAR theranostic platform combines two key technologies – uTRACE and uTREAT both targeting the uPAR receptor. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight’s ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers.

For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com

www.curasight.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/curasight/r/curasight-to-hold-meetings-in-san-francisco-during-j-p–morgan-healthcare-conference-week,c4288616

The following files are available for download:

https://mb.cision.com/Main/19744/4288616/3862590.pdf

Curasight Press release – JPM 26

Cision View original content:https://www.prnewswire.com/news-releases/curasight-to-hold-meetings-in-san-francisco-during-jp-morgan-healthcare-conference-week-302652512.html

SOURCE Curasight

Market Opportunity
Cypherium Logo
Cypherium Price(CPH)
$0,003164
$0,003164$0,003164
-%2,01
USD
Cypherium (CPH) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Why It Could Outperform Pepe Coin And Tron With Over $7m Already Raised

Why It Could Outperform Pepe Coin And Tron With Over $7m Already Raised

The post Why It Could Outperform Pepe Coin And Tron With Over $7m Already Raised appeared on BitcoinEthereumNews.com. Crypto News 17 September 2025 | 20:26 While meme tokens like Pepe Coin and established networks such as Tron attract headlines, many investors are now searching for projects that combine innovation, revenue-sharing and real-world utility. BlockchainFX ($BFX), currently in presale at $0.024 ahead of an expected $0.05 launch, is quickly becoming one of the best cryptos to buy today. With $7m already secured and a unique model spanning multiple asset classes, it is positioning itself as a decentralised super app and a contender to surpass older altcoins. Early Presale Pricing Creates A Rare Entry Point BlockchainFX’s presale pricing structure has been designed to reward early participants. At $0.024, buyers secure a lower entry price than later rounds, locking in a cost basis more than 50% below the projected $0.05 launch price. As sales continue to climb beyond $7m, each new stage automatically increases the token price. This built-in mechanism creates a clear advantage for early investors and explains why the project is increasingly cited in “best presales to buy now” discussions across the crypto space. High-Yield Staking Model Shares Platform Revenue Beyond its presale appeal, BlockchainFX is creating a high-yield staking model that gives holders a direct share of platform revenue. Every time a trade occurs on its platform, 70% of trading fees flow back into the $BFX ecosystem: 50% of collected fees are automatically distributed to stakers in both BFX and USDT. 20% is allocated to daily buybacks of $BFX, adding demand and price support. Half of the bought-back tokens are permanently burned, steadily reducing supply. Rewards are based on the size of each member’s BFX holdings and capped at $25,000 USDT per day to ensure sustainability. This structure transforms token ownership from a speculative bet into an income-generating position, a rare feature among today’s altcoins. A Multi-Asset Platform…
Share
BitcoinEthereumNews2025/09/18 03:35
Missouri Considers Bitcoin Reserve Fund using Donations

Missouri Considers Bitcoin Reserve Fund using Donations

The post Missouri Considers Bitcoin Reserve Fund using Donations appeared on BitcoinEthereumNews.com. Missouri legislators have taken a significant step by introducing
Share
BitcoinEthereumNews2026/02/21 14:17
Pakistan launches crypto sandbox to advance regulation plans: Details

Pakistan launches crypto sandbox to advance regulation plans: Details

The post Pakistan launches crypto sandbox to advance regulation plans: Details appeared on BitcoinEthereumNews.com. Pakistan has officially launched a crypto testing
Share
BitcoinEthereumNews2026/02/21 14:35